You are here

Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders

CORAL GABLES, Fla., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic, neuromuscular and neurological diseases, today announced that the Company has responded to the February 4, 2019 letter that the Company received from Senator Bernie Sanders. The Company’s response letter, dated February 21, 2019, is posted at www.catalystpharma.com in the Investor section under Events and Presentations.
Thursday, February 21, 2019 - 09:00